Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

  • Post published:September 15, 2022
  • Post category:Press Release
Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

  • Post published:August 12, 2022
  • Post category:Press Release
Read more about the article Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

  • Post published:July 20, 2022
  • Post category:Press Release
Read more about the article U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

  • Post published:June 17, 2022
  • Post category:Press Release
Read more about the article Mydecine Announces Reverse Stock-Split

Mydecine Announces Reverse Stock-Split

  • Post published:April 13, 2022
  • Post category:Press Release
Read more about the article Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

  • Post published:April 1, 2022
  • Post category:Press Release
Read more about the article Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement

  • Post published:March 31, 2022
  • Post category:Press Release
Read more about the article Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

  • Post published:March 24, 2022
  • Post category:Press Release
Read more about the article Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

  • Post published:March 1, 2022
  • Post category:Press Release
Read more about the article Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

  • Post published:February 16, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More